John T Lis

US Patent:

7435542, Oct 14, 2008

Filed:

Jun 24, 2003

Appl. No.:

10/602837

Inventors:

Hua Shi - Ithaca NY, US
John T. Lis - Ithaca NY, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435 6, 435 912

Abstract:

A method of identifying RNA ligands which bind to a target molecule by treating a first pool of RNA ligands that collectively bind more than one target under conditions effective to reduce the concentration or eliminate the presence of one or more predominate target-binding RNA ligands from the first pool of RNA ligands; amplifying the RNA ligands in the treated first pool, thereby forming a second pool of RNA ligands that is enriched in one or more non-predominate target-binding RNA ligands of the first pool but not the one or more predominate target-binding RNA ligands thereof; and identifying one or more predominate target-binding RNA ligands that are present in the second pool at a higher concentration than other target-binding RNA ligands. Oligonucleotides and kits which can be used in practicing the present invention are also disclosed, as are aptamers that bind to a heat shock factor protein and their use.

US Patent:

7601823, Oct 13, 2009

Filed:

Oct 24, 2005

Appl. No.:

11/256726

Inventors:

Li Niu - Loundonville NY, US
Zhen Huang - Albany NY, US
Hua Shi - Ithaca NY, US
John T. Lis - Ithaca NY, US

Assignee:

Cornell University - Ithaca NY
The Research Foundation of State University of New York - Albany NY

International Classification:

C07H 21/02

US Classification:

536 231, 506 16, 506 13, 506 23, 506 7

Abstract:

The present invention relates to novel nucleic acid ligands or aptamers that bind to and inhibit the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. Also disclosed is a novel combination of technologies, i. e. , SELEX and laser pulse photolysis for the selection and screening of aptamers that inhibit receptor function and are useful therefore, in the treatment of diseases associated with excessive activation of ionotropic glutamate receptors.

US Patent:

8076467, Dec 13, 2011

Filed:

Oct 13, 2009

Appl. No.:

12/578231

Inventors:

Li Niu - Loudonville NY, US
Zhen Huang - Albany NY, US
Hua Shi - Ithaca NY, US
John T. Lis - Ithaca NY, US

Assignee:

The Research Foundation of State University of New York - Albany NY
Cornell University - Ithaca NY

International Classification:

C07H 21/02
C07H 21/04
C40B 40/06
C40B 40/00
C40B 50/00
C40B 30/00
A61K 48/00

US Classification:

536 231, 506 16, 506 13, 506 23, 506 7, 514 44 R

Abstract:

The present invention relates to novel nucleic acid ligands or aptamers that bind to and inhibit the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. Also disclosed is a novel combination of technologies, i. e. , SELEX and laser pulse photolysis for the selection and screening of aptamers that inhibit receptor function and are useful therefore, in the treatment of diseases associated with excessive activation of ionotropic glutamate receptors.

US Patent:

8445655, May 21, 2013

Filed:

Jun 18, 2007

Appl. No.:

12/305102

Inventors:

Michael Kotlikoff - Ithaca NY, US
John T. Lis - Ithaca NY, US
Bo Shui - Ithaca NY, US
Hua Shi - Ithaca NY, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

C07H 21/02
C12N 15/00
C12Q 1/68
C07H 21/04

US Classification:

536 231, 536 245, 435 61, 435455

Abstract:

The present invention relates to a nucleic acid aptamer having a first domain that binds to a fluorescent protein. The nucleic acid aptamer forms a molecular complex whereby the aptamer binds a fluorescent protein at the first domain. A constructed DNA molecule, expression systems, and host cells containing the molecular complex are also disclosed. The invention also relates to a system containing a first DNA molecule encoding the nucleic acid aptamer of the present invention and a second DNA molecule encoding a fluorescent protein capable of being bound by the first domain. Methods of detecting a molecular target and determining location of a molecular target using the nucleic acid aptamer of the invention are also disclosed.

US Patent:

8450468, May 28, 2013

Filed:

Dec 12, 2011

Appl. No.:

13/323161

Inventors:

Li Niu - Loudonville NY, US
Zhen Huang - Albany NY, US
Hua Shi - Ithaca NY, US
John T. Lis - Ithaca NY, US

Assignee:

The Research Foundation for the State University of New York - Albany NY
Cornell University - Ithaca NY

International Classification:

A61K 48/00
C07H 19/00
C07H 21/00
C07H 21/02

US Classification:

536 221, 536 231, 514 44 R

Abstract:

The present invention relates to novel nucleic acid ligands or aptamers that bind to and inhibit the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. Also disclosed is a novel combination of technologies, i. e. , SELEX and laser pulse photolysis for the selection and screening of aptamers that inhibit receptor function and are useful therefore, in the treatment of diseases associated with excessive activation of ionotropic glutamate receptors.

US Patent:

20030175730, Sep 18, 2003

Filed:

Jun 14, 2002

Appl. No.:

10/173368

Inventors:

Hua Shi - Ithaca NY, US
John Lis - Ithaca NY, US

International Classification:

A01K067/033
C12Q001/68
C07H021/04
C12N015/87

US Classification:

435/006000, 435/455000, 435/320100, 435/325000, 800/008000, 536/023200

Abstract:

The present invention relates to a monovalent RNA aptamer that binds to Drosophila splicing factor B52 and a multivalent RNA aptamer that includes at least two RNA aptamer sequences linked together. Also disclosed are isolated or constructed DNA molecules which encode either a monovalent RNA aptamer or a multivalent RNA aptamer of the present invention, an engineered gene encoding a multivalent RNA aptamer of the present invention, and host cells and expression systems which contain either a heterologous DNA molecule or a heterologous gene of the present invention. Further aspects of the present invention relate to a method of expressing a multivalent RNA aptamer in a cell, a method of increasing activity of a splicing factor protein in a cell, and a method of inhibiting activity of a target molecule in a cell. A transgenic non-human organism whose somatic and germ cell lines contain an engineered gene encoding a multivalent RNA aptamer is also disclosed.

US Patent:

20050176026, Aug 11, 2005

Filed:

Sep 3, 2004

Appl. No.:

10/934894

Inventors:

Carl Franck - Ithaca NY, US
John Lis - Ithaca NY, US
Amber Boehm - Ithaca NY, US

International Classification:

C12Q001/68
G01N033/53

US Classification:

435006000, 435007100

Abstract:

The present invention relates to methods of reacting a receptor and a target. A reaction liquid having one or more receptors and one or more targets is provided. A confining fluid that is immiscible with the reaction liquid is positioned adjacent a first surface of the reaction liquid. The confining fluid is stirred, thereby allowing the one or more receptors and one or more targets to react with each other. Alternatively, a coverplate is positioned adjacent a first surface of the reaction liquid and reaction between the receptors and targets occurs upon rotating the coverplate. Also disclosed is a system for reacting a receptor and a target. The system involves a holding device having a reaction liquid, a confining fluid adjacent a first surface of the reaction liquid, and a mixing device positioned within the confining fluid. Alternatively, the system can be a substrate, a rotating coverplate, and a reaction liquid between the substrate and the coverplate.

US Patent:

20050282190, Dec 22, 2005

Filed:

Apr 11, 2005

Appl. No.:

11/103122

Inventors:

Hua Shi - Ithaca NY, US
John Lis - Ithaca NY, US

International Classification:

C12Q001/68
C07H021/04

US Classification:

435006000, 536024300

Abstract:

The present invention relates to a nucleic acid molecule comprised of first and second nucleic acid elements that each bind a target molecule, and a three-way junction operably linking the first and second nucleic elements. Also disclosed is an RNA scaffold comprising first and second RNA receptor regions operably linked by a three-way junction, wherein the first and second RNA receptor regions each comprise a stem defined by at least two sets of consecutive, canonic, paired bases. A method of using a multivalent nucleic acid aptamer to bring a first and second target molecule into proximity of one another is also disclosed. Also disclosed are constructed DNA molecules, engineered genes, transgenic non-human organisms, methods of modifying activity of target molecules, and functional RNA molecules comprising an RNA scaffold and one or more functional modules. A method for modular design and construction of nucleic acid molecules is also disclosed.